Juliana Daley
About Juliana Daley
Juliana Daley, CPA, is an independent director of PMGC Holdings Inc. (ticker ELAB) appointed in June 2023; she is 36 years old and brings 11+ years of public-company accounting, controller, and financial reporting experience across the U.S. and Canada . She currently serves as Manager of Accounting at Anavex Life Sciences Corp. (NASDAQ: AVXL) since July 2021 and has been designated by ELAB’s Board as an “audit committee financial expert,” reflecting deep accounting/financial management expertise .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Anavex Life Sciences Corp. (NASDAQ: AVXL) | Manager of Accounting | Jul 2021–present | Leads internal reporting, budgeting; supports SOX audits, quarterly reviews, IT audits |
| Treewalk (formerly ACM Management, Inc.) | Manager, Financial Reporting & Advisory | Oct 2015–Jul 2021 | Managed quarterly/annual reporting packages; assurance engagements end-to-end |
| Makena Resources Inc. (CSE: MKNA) | Chief Financial Officer | Apr 2018–Apr 2019 | CFO during corporate transactions |
| Naked Brand Group Inc. (NASDAQ: NAKD) | CFO (Mar–Jun 2018); Controller (Aug 2013–Apr 2015) | 2013–2015; 2018 | Led ERP/EDI implementation, inventory, IT, office admin; short-term CFO through merger completion |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Vegano Foods (CSE: VAGN) | Independent Director; Audit Committee Chair | Aug 2021–Jul 2022 | Served through Vegano’s February 2022 IPO |
Board Governance
- Independence: Board determined Ms. Daley is independent under Nasdaq rules .
- Committees: Chair, Audit Committee; Member, Compensation Committee; Member, Nominating & Corporate Governance Committee .
- Audit Committee qualification: Board designated Daley as an audit committee financial expert; Audit Committee met four times in FY2024 and holds private sessions with external and internal auditors .
- Board activity: The Board held six meetings in FY2024 .
- Annual Meeting attendance policy: Company does not require directors to attend the Annual Stockholders Meeting .
- Related-party oversight: Audit Committee reviews and approves related-party transactions; scope includes financial reporting integrity, internal controls, risk management, compliance, cybersecurity, and anti-fraud .
Fixed Compensation
| Component | Structure | Amount/Timing | Notes |
|---|---|---|---|
| Annual cash retainer | Independent director compensation | $55,500 per year; paid quarterly $13,875 | As of proxy date; reimburses reasonable travel/out-of-pocket expenses |
| FY2024 cash actually paid | Director compensation table (Daley) | $55,000 (cash) | No stock/option awards shown for Daley in FY2024; reflects year-specific amount |
| Meeting/committee fees | Not specifically disclosed | — | Company notes past use of cash and stock options; no explicit chair/member fees disclosed |
Performance Compensation
| Award Type | Grant/Date | Number of Shares | Exercise Price | Vesting Schedule | Term | Notes |
|---|---|---|---|---|---|---|
| Non-statutory stock options | Jun 1, 2023 | 49 shares (pre-adjusted); 14 adjusted | $7,000 per share (pre-adjusted); $24,500 adjusted | 25% at 1-year; remaining 75% ratable over 36 months | 10 years | Granted to independent director nominees, including Julianna (sic) Daley |
| Non-statutory stock options | Jun 1, 2023 | 172 shares | $7,000 per share | 25% at 1-year; remaining 75% ratable over 36 months | 10 years | Second disclosure of same date showing higher grant figure to Daley and others |
- Disclosure inconsistency: The proxy contains conflicting option grant counts for Jun 1, 2023 (49 vs. 172 shares) with identical strike/vesting/term—this raises a disclosure-quality red flag that the Audit Chair should address for clarity .
Other Directorships & Interlocks
| Company | Role | Interlock/Overlap | Potential Conflict Notes |
|---|---|---|---|
| Vegano Foods (CSE: VAGN) | Independent Director; Audit Chair (Aug 2021–Jul 2022) | None identified with ELAB | Prior role; no disclosed transactions with ELAB |
Expertise & Qualifications
- CPA; 11+ years in public-company accounting, financial reporting, SOX-support, and operational systems implementations across U.S./Canada .
- Designated audit committee financial expert with financial management expertise; independent under Nasdaq rules .
- Experience includes CFO/controller roles and managing assurance engagements, supporting readiness for audits and quarterly reviews .
Equity Ownership
| Holder | Common Shares (Direct) | Options Exercisable ≤60 Days | Series B Preferred | % of Common | % of Voting Stock |
|---|---|---|---|---|---|
| Juliana Daley | 1 | 9 | 0 | <1% | <1% |
| Notes | — | Options reflect beneficial ownership within 60 days of Oct 10, 2025 | — | Computed vs 744,121 common shares | Voting includes Common + Series B voting together |
| Citations: |
- Hedging policy: Directors/officers prohibited from hedging company securities (e.g., prepaid forwards, swaps, collars) .
- Pledging: No pledging disclosures for Daley; no shares pledged disclosed in proxy .
Governance Assessment
-
Strengths
- Independence and audit expertise: Daley is independent and serves as Audit Chair with “financial expert” designation, overseeing related-party reviews, internal controls, audit quality, compliance, and cybersecurity—important for investor confidence given ELAB’s complexity .
- Audit Committee practices: Private sessions with auditors and focus on PCAOB 1301 communications indicate robust oversight mechanics .
-
Weaknesses / RED FLAGS
- Conflicting equity grant disclosures: Different share counts reported for Jun 1, 2023 options (49 vs. 172 shares) create uncertainty about director equity awards; the Audit Chair should ensure reconciliation and accurate footnoting in future filings (RED FLAG) .
- Extensive related-party arrangements at ELAB: Significant consulting, milestone bonuses, secondment agreements, and preferred equity ties to the Non-Executive Chairman (Northstrive) and Non-Employee CEO (GB Capital) indicate heightened related-party risk; Audit Chair’s oversight of these transactions is crucial (RED FLAG) .
- Board meeting attendance rates not disclosed; company does not require director attendance at Annual Meetings—an investor governance negative versus best practice norms .
- Director stock ownership guidelines not disclosed; absence may weaken alignment signals for independent directors .
-
Signals to monitor
- Clarity and consistency in equity disclosures and award accounting for directors (address the Jun 1, 2023 discrepancy) .
- Robust documentation of Audit Committee review of related-party transactions (Northstrive/GB Capital) and fee structures, including milestone/valuation bonuses that may influence governance optics .
- Continued independence of Audit Committee under evolving financing structures (e.g., pre-paid purchase facility, commitment shares), ensuring proper fair-value and disclosure controls .
Overall, Daley’s audit chair role and CPA background are positives for board effectiveness and financial oversight, but ELAB’s heavy related-party exposure and inconsistent director equity disclosures present governance risks that warrant vigilant Audit Committee oversight and improved transparency .